Matt O'Brien
Stock Analyst at Piper Sandler
(2.20)
# 2,764
Out of 5,170 analysts
200
Total ratings
41.92%
Success rate
-5.8%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNMD CONMED | Downgrades: Neutral | $55 → $39 | $36.80 | +5.98% | 15 | Mar 17, 2026 | |
| TNDM Tandem Diabetes Care | Upgrades: Overweight | $21 → $33 | $24.63 | +33.98% | 11 | Mar 17, 2026 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $50 → $28 | $25.68 | +9.03% | 6 | Feb 26, 2026 | |
| TMDX TransMedics Group | Maintains: Overweight | $140 → $160 | $113.72 | +40.70% | 14 | Feb 25, 2026 | |
| GMED Globus Medical | Reiterates: Overweight | $90 → $115 | $86.30 | +33.26% | 13 | Jan 8, 2026 | |
| KMTS Kestra Medical Technologies | Maintains: Overweight | $27 → $30 | $19.56 | +53.37% | 2 | Dec 12, 2025 | |
| TELA TELA Bio | Reiterates: Neutral | $2 → $1.25 | $0.76 | +65.23% | 7 | Nov 14, 2025 | |
| SI Shoulder Innovations | Reiterates: Overweight | $18 | $15.05 | +19.60% | 2 | Nov 12, 2025 | |
| DXCM DexCom | Maintains: Overweight | $100 → $75 | $67.27 | +11.49% | 13 | Oct 31, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Overweight | $20 → $25 | $12.72 | +96.54% | 4 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $26 → $32 | $10.80 | +196.30% | 2 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $155 → $82 | $84.36 | -2.80% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $16.54 | +33.01% | 3 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $10.86 | +65.75% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $12 | $8.63 | +39.05% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $165 | $102.09 | +61.62% | 10 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $3.57 | -1.96% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $107.05 | +30.78% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $228.63 | +35.59% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $337.35 | -2.18% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $29.03 | +72.24% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $17.47 | -8.41% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $69.89 | +64.54% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $4.03 | +197.77% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $339.76 | +23.62% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $86.87 | +3.60% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $12.77 | +95.77% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $0.85 | +251.25% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $3.53 | +27.48% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $89.84 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $4.64 | +223.28% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $70.71 | +53.80% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $16.66 | +380.19% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $4.30 | +179.07% | 1 | Jun 24, 2020 |
CONMED
Mar 17, 2026
Downgrades: Neutral
Price Target: $55 → $39
Current: $36.80
Upside: +5.98%
Tandem Diabetes Care
Mar 17, 2026
Upgrades: Overweight
Price Target: $21 → $33
Current: $24.63
Upside: +33.98%
PROCEPT BioRobotics
Feb 26, 2026
Maintains: Overweight
Price Target: $50 → $28
Current: $25.68
Upside: +9.03%
TransMedics Group
Feb 25, 2026
Maintains: Overweight
Price Target: $140 → $160
Current: $113.72
Upside: +40.70%
Globus Medical
Jan 8, 2026
Reiterates: Overweight
Price Target: $90 → $115
Current: $86.30
Upside: +33.26%
Kestra Medical Technologies
Dec 12, 2025
Maintains: Overweight
Price Target: $27 → $30
Current: $19.56
Upside: +53.37%
TELA Bio
Nov 14, 2025
Reiterates: Neutral
Price Target: $2 → $1.25
Current: $0.76
Upside: +65.23%
Shoulder Innovations
Nov 12, 2025
Reiterates: Overweight
Price Target: $18
Current: $15.05
Upside: +19.60%
DexCom
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $75
Current: $67.27
Upside: +11.49%
Alphatec Holdings
Oct 31, 2025
Reiterates: Overweight
Price Target: $20 → $25
Current: $12.72
Upside: +96.54%
Oct 29, 2025
Reiterates: Overweight
Price Target: $26 → $32
Current: $10.80
Upside: +196.30%
Oct 24, 2025
Maintains: Overweight
Price Target: $155 → $82
Current: $84.36
Upside: -2.80%
Oct 10, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $16.54
Upside: +33.01%
Aug 18, 2025
Initiates: Overweight
Price Target: $18
Current: $10.86
Upside: +65.75%
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $8.63
Upside: +39.05%
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $102.09
Upside: +61.62%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $3.57
Upside: -1.96%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $107.05
Upside: +30.78%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $228.63
Upside: +35.59%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $337.35
Upside: -2.18%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $29.03
Upside: +72.24%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $17.47
Upside: -8.41%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $69.89
Upside: +64.54%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $4.03
Upside: +197.77%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $339.76
Upside: +23.62%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $86.87
Upside: +3.60%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $12.77
Upside: +95.77%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $0.85
Upside: +251.25%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $3.53
Upside: +27.48%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $89.84
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $4.64
Upside: +223.28%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $70.71
Upside: +53.80%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $16.66
Upside: +380.19%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $4.30
Upside: +179.07%